- Home
- AEMD vs MBIO Comparison
AEMD vs MBIO Comparison
Compare AEMD & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEMD
- MBIO
- Stock Information
- Founded
- AEMD 1984
- MBIO 2015
- Country
- AEMD United States
- MBIO United States
- Employees
- AEMD N/A
- MBIO N/A
- Industry
- AEMD Medical/Dental Instruments
- MBIO Biotechnology: Pharmaceutical Preparations
- Sector
- AEMD Health Care
- MBIO Health Care
- Exchange
- AEMD Nasdaq
- MBIO Nasdaq
- Market Cap
- AEMD 8.2M
- MBIO 7.3M
- IPO Year
- AEMD N/A
- MBIO N/A
- Fundamental
- Price
- AEMD $0.42
- MBIO $1.40
- Analyst Decision
- AEMD Strong Buy
- MBIO Strong Buy
- Analyst Count
- AEMD 1
- MBIO 1
- Target Price
- AEMD $7.00
- MBIO $100.00
- AVG Volume (30 Days)
- AEMD 260.5K
- MBIO 156.6K
- Earning Date
- AEMD 02-12-2025
- MBIO 03-25-2025
- Dividend Yield
- AEMD N/A
- MBIO N/A
- EPS Growth
- AEMD N/A
- MBIO N/A
- EPS
- AEMD N/A
- MBIO N/A
- Revenue
- AEMD N/A
- MBIO N/A
- Revenue This Year
- AEMD N/A
- MBIO N/A
- Revenue Next Year
- AEMD N/A
- MBIO N/A
- P/E Ratio
- AEMD N/A
- MBIO N/A
- Revenue Growth
- AEMD N/A
- MBIO N/A
- 52 Week Low
- AEMD $0.24
- MBIO $1.36
- 52 Week High
- AEMD $1.85
- MBIO $67.00
- Technical
- Relative Strength Index (RSI)
- AEMD 34.08
- MBIO 23.45
- Support Level
- AEMD $0.40
- MBIO $1.39
- Resistance Level
- AEMD $0.60
- MBIO $1.60
- Average True Range (ATR)
- AEMD 0.05
- MBIO 0.22
- MACD
- AEMD -0.01
- MBIO 0.08
- Stochastic Oscillator
- AEMD 13.41
- MBIO 2.37
About AEMD Aethlon Medical Inc.
Aethlon Medical Inc is a medical therapeutic company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.